Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.

Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes. Improving outcomes in Psoriatic Arthritis Psoriatic Arthritis (PsA) is a form of arthritis which is found in approximately 30% of people who have the skin condition, Psoriasis. Frequently debilitating and progressive, achieving a good outcome for a person with PsA is made difficult by late diagnosis, disease clinical features and in many cases, failure to adequately control features of inflammation. Research studies from individual centres have certainly contributed to our understanding of why people develop PsA but to adequately address the major areas of unmet need, multi-centre, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient representative organisations (see appendix). In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. The participation of patient research partners in all stages of the work of HIPPOCRATES is highlighted. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for improvements in short-term and long-term outcomes.

Informations de copyright

© The Author(s), 2023.

Déclaration de conflit d'intérêts

OF has received grants from AbbVie, Bristol Myers Squibb, Janssen, Eli-Lilly, Novartis, Pfizer and UCB. DS has received grants from AbbVie, Janssen, Eli-Lilly and Novartis. SK is an employee of and has stocks or stock options in Bristol Myers Squibb. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli-Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. FB and MK have received grants/research support from AbbVie, Amgen, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli-Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. AB has received grants/research support from Pfizer, Bristol Myers Squibb, Galapagos and Schiper Medicine and received speaker fees from Chugai-Roche. AV, MKl and JMS – no conflicts of interest to declare. CSG has received grants/research support from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Eli-Lilly, Istesso, Janssen, MedAnnex, MiroBio, Pfizer, UCB; worked as a consultant for AstraZeneca, Bristol Myers Squibb, Janssen, MedAnnex, MiroBio; and has been paid as a speaker for AbbVie and UCB. BBD was an employee and then a consultant of Novartis Pharma AG. CH is an employee of Novartis Pharma AG. SS has received institutional research support from Amgen (previously Celgene), Boehringer Ingelheim, Bristol Myers Squibb, Eli-Lilly, GSK, Janssen and UCB; consultancy/speaker fees from AbbVie, Amgen, AstraZeneca, Eli-Lilly, GSK, Janssen and UCB. MdW: Over the last 3 years Stichting Tools has received fees for lectures or consultancy provided by Maarten de Wit from Celgene, Eli-Lilly, Pfizer and UCB.